German General Practice. Drugs Aging. 2021 Aug;38(8):725-733. Greten S, Müller-Funogea JI, Wegner F, Höglinger GU, Simon N, Junius-Walker U , Gerbel S, Krause O, Klietz M. Drug safety profiles in geriatric patients
L, Panagiota V, Fröhlich T, Schultze-Florey C, Wattjes MP, Beutel G, Eder M, David S, Körner S, Höglinger G, Stangel M, Ganser A, Koenecke C, Skripuletz T. Neurological management and work-up of neurotoxicity
Satishchandra P, Hoo FK, Dalmau J, Oreja-Guevara C, Ferreira MLB, Pfausler B, Michael BD, Tagliavini F, Hoglinger G, Endres M, Klein C, Hemmer B, Carroll W, Sejvar J, Solomon T. A call for a global COVID-19 Neuro [...] review. Patient Educ Couns 2020 DOI: S0738-3991(20)30547-4 Huber M, Rogozinski S, Puppe W, Framme C, Hoglinger G, Hufendiek K, Wegner F. Postinfectious Onset of Myasthenia Gravis in a COVID-19 Patient. Front [...] Piepel C, Lanznaster J, Rieg S, Prasser F, Pilgram L, Spottke A, Klockgether T, Klein C, Hopfner F, Hoglinger GU, LEOSS Study Group. Outcomes of SARS-CoV-2 Infections in Patients With Neurodegenerative Diseases
Lilia Goudeva, Rainer Blasczyk, Armin Koch , Britta Maecker-Kolhoff, Britta Eiz-Vesper, Günter Höglinger, and Thomas Skripuletz. 2024. “Directly Isolated Allogeneic Virus-Specific T Cells in Progressive
Lilia Goudeva, Rainer Blasczyk, Armin Koch , Britta Maecker-Kolhoff, Britta Eiz-Vesper, Günter Höglinger, and Thomas Skripuletz. 2024. “Directly Isolated Allogeneic Virus-Specific T Cells in Progressive [...] Lilia Goudeva, Rainer Blasczyk, Armin Koch , Britta Maecker-Kolhoff, Britta Eiz-Vesper, Günter Höglinger, and Thomas Skripuletz. 2024. “Directly Isolated Allogeneic Virus-Specific T Cells in Progressive
Clinic, MHH: ‘Innovative biomaterials and the future of mesenchymal ʽstemʼ cells’ Prof. Dr. Günter Höglinger Department of Neurology, MHH: ‘Regeneration in Neurodegenerative Diseases - What is Possible?’ 17
Release. Henkel L.M, Kankowski S, Moellenkamp T.M, Smandzich N.J, Schwarz S, Di Fonzo A, Göhring G, Höglinger G, Wegner F. (2023) Cells , 12 , 223. https://doi.org/10.3390/cells12020223 In vitro impact of platinum
*equal contribution MOEHN N, WATTJES MP, ADAMS O, NAY S, TKACHENKO D, SALGE F, HEINE J, PARS K, HOEGLINGER G, RESPONDEK G, STANGEL M, SKRIPULETZ T, JACOBS R, SUEHS KW. PD-1-Inhibitor pembrolizumab for treatment